Sustained antiemetic efficacy of fosnetupitant versus aprepitant in carboplatin-based chemotherapy: a retrospective observational study
{{output}}
Background: Carboplatin (CBDCA) is highly emetogenic when administered at an area under the curve (AUC) ≥ 4, requiring triple antiemetic therapy, including an NK1 receptor antagonist (NK1 RA). Fosnetupitant (F-NTP), a long-actin... ...
